Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Continued Democratization of Personalized Healthcare

A show of hands: How many people were adept at taking an in-home health test before the pandemic? The answer: probably not many. The pandemic changed that, along with so many other healthcare processes. Taking a COVID test, a healthcare assessment, or even a virtual patient visit weren’t things most were used to doing at…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

A show of hands: How many people were adept at taking an in-home health test before the pandemic? The answer: probably not many. The pandemic changed that, along with so many other healthcare processes. Taking a COVID test, a healthcare assessment, or even a virtual patient visit weren’t things most were used to doing at home a few short years ago, but the experience taught millions of people a valuable lesson: personalized healthcare is essential and should be a part of the healthcare journey moving forward.

Technology is leading the way in democratizing personalized healthcare. Wearable technology, from fitness monitoring to biosensors, can give patients and providers valuable health information and provide new tools for improving health outcomes. Advanced data gathering creates health equity for everyone.

David Kemp, host of Highway to Health, spoke with two women working on the front lines of that personalized healthcare mission. Sherlock Biosciences’ Julie Garlikov, Chief Commercial Officer, and Karen Davies, Chief Development Officer, gave Kemp a window into the science behind molecular diagnostics, which is changing the game of testing to a more democratized and decentralized approach to personalized healthcare.

What types of testing does Sherlock Biosciences do?

“We’re a pre-commercial company looking at the intersection of our chemistries and technologies and where our tests perform the best,” Garlikov said. “And then we talked with many consumers to understand where they want to test and what they want to test for at home. And when we put those two together, the intersection is in the areas of respiratory and sexual health. And when I say respiratory, I’m not just talking COVID tests. I’m talking about flu, or RSV, or even, in the future, strep throat, or walking pneumonia.”

Kemp’s conversation with Garlikov and Davies includes the following:

  • Creating efficiencies through at-home testing
  • The advancing technologies creating these new testing solutions
  • The importance of advanced diagnostics for rural and underserved communities

“Accessibility is the big thing,” Davies said. “And portability. A small, easy-to-run test; you can stick it in your backpack, you can stick it in your suitcase, or you can mail order it if you live in a remote region. If I’ve got that test in my backpack or I’ve got that test at home, I can run it. It’s negative most of the time. And so I can provide self-care. If it’s positive, I know it’s worth the trip to see my doctor.”

About Karen

Karen Davies is a mechanical engineer with a BS from Stanford University. Her twenty-plus-year career in medical devices includes product development, technical leadership, program management, quality and regulatory compliance, and strategic planning. She is a sought-out mentor by personnel in multiple functional areas, including Instrumentation, Assay Development, and Marketing.

About Julie

Julie Garlikov is a full-stack, omnichannel, B2C/B2B marketing & commercialization executive with numerous successes in accelerating growth for digital consumer healthcare and health, wellness & beauty (skincare, vitamins, nutrition), and beverage brands. Her passion lies in building and scaling brands to take them to the next level. Garlikov holds an MBA in marketing from Columbia Business School and a BA from the University of California, Berkeley.

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

July partnerships show hospitals aligning without ownership change

July partnerships show hospitals aligning without ownership change

A July McDermott Will & Schulte analysis and four July partnership announcements tracked by Becker’s Hospital Review point to affiliation models that stop short of mergers. St. Christopher’s signed a nonbinding letter of intent with Nemours, Jefferson and Temple; Palomar UC San Diego Health began operating July 1 under a joint powers authority. Several announcements explicitly rule out ownership change, shifting the work to contracts covering governance and other terms.

  • 01In an alliance, the contract does the integrating that an org chart does in a merger: McDermott Will & Schulte says governance design, exclusivity, antitrust review, community commitments and exit rights all have to be settled before signing.
  • 02Purchasing is now explicitly on the table in at least one no-ownership deal, the St. Peter's Health and Billings Clinic-Logan Health talks in Montana, which means shared supply contracts can arrive without a change of control.

Sep 19, 2026

Eye telemedicine hits limits without home retinal imaging

Eye telemedicine hits limits without home retinal imaging

An Ophthalmology Times commentary by T.Y. Alvin Liu, Ferdinand Hui and Phillip Phan sorts eye patients into three telemedicine tiers by clinical need. Patients needing regular OCT scans benefit less unless a home device can send the image. Video tools already sit inside Epic and Cerner; the deciding purchase for retina clinics is the imaging device in the patient's living room.

  • 01The dividing line for eye telemedicine is imaging, not video: patients who need regular OCT scans benefit less from remote visits unless a device at home can send the scan, so a video license alone shifts few of those encounters.
  • 02The provider-side requirement, a HIPAA-compliant secured video platform, was already built into Epic and Cerner by 2020; the patient-side requirements (1.5 MB up and down bandwidth, a quiet private room, comfort with the technology) sit outside the health system's control and are the ones worth screening for at scheduling.
  • 03Self-administered home color fundus photography for tracking non-proliferative diabetic retinopathy was named as the nearer route into retina telemedicine; home OCT for wet AMD is the harder gate and the device to watch.

Sep 19, 2026

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Wolters Kluwer Health argues value-based care software is judged on whether customers hit incentive thresholds and avoid penalties. A Fierce Healthcare-reported survey it cites puts value-based care at a quarter or more of revenue for 30% of organizations. The analysis is a vendor publication that ends by pitching its own UpToDate Connect API.

  • 01The sharper question for any population health or care coordination platform is whether it changes what a clinician does at the moment of decision, or only reports afterward what happened. Wolters Kluwer's reading of the evidence is that many platforms still struggle with the first.
  • 02Vendors selling into value-based contracts now face a build-or-license decision on clinical content, because Wolters Kluwer names current, trusted content, consistent clinician adoption across sites, and a traceable link from guidance to quality metrics as the three hard problems.

Sep 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512